Fewer Patients in the Real-World vs Clinical Trials May Achieve Satisfactory Response to TNFis in axSpA
Researchers investigated the treatment response of patients receiving tumor necrosis factor inhibitors in the real-world vs clinical trials.
Tumor Necrosis Factor Inhibitors
Anti-TNF Agents May Lower Alzheimer Disease Risk for Psoriasis, Rheumatoid Arthritis
A subset of patients at risk for Alzheimer disease because of systemic inflammation may benefit from receiving a tumor necrosis factor (TNF) blocking agent.
TNFi Combination Therapy vs Monotherapy Improves Drug Survival in Psoriatic Arthritis
Researchers compared the effectiveness of tumor necrosis factor inhibitor combination therapy vs monotherapy in psoriatic arthritis.
Demographic Characteristics and Clinical Factors Affect Anti-TNF Treatment Adherence in Rheumatoid Arthritis
Researchers determined the adherence to subcutaneous antitumor necrosis factor agents in rheumatoid arthritis, and evaluated the influence of injection site pain and skin perceptions on treatment adherence.
Predictors of Response to Anti-TNF Therapy in Axial Spondyloarthritis
Researchers sought to determine the modifiable and nonmodifiable risk factors affecting anti-TNF response in axSpA.
Medication Persistence in Ankylosing Spondylitis Varies by Country
Real-world ankylosing spondylitis treatment patterns appear to vary by country.
Discordance Between Patient and Evaluator Global Assessments Affects TNFi Retention Rates in SpA
High baseline patient vs evaluator global assessment linked to lower TNFi retention in spondyloarthritis.
Switching of TNFis Linked to Lower Drug Survival and Response Rates in Psoriatic Arthritis
Researchers assessed the long-term effectiveness of tumor necrosis factor inhibitors (TNFis) in patients with psoriatic arthritis who were exposed to at least 1 TNFi.
Few Serious Infections in Offspring Exposed to Non-TNFi Biologics, Tofacitinib
Researchers compared the risk for serious infections in offspring of mothers with chronic inflammatory diseases who received non-TNFi biologics or tofacitinib during pregnancy vs offspring who were unexposed, but exposed to TNFi in utero.
Long-Term TNFi Therapy Outcomes in Psoriatic Arthritis
This study was conducted to describe patterns of first and subsequent TNFi use and response to long-term TNFi therapy in patients with PsA.
-
Loading...
-
Loading...
Next post in Psoriatic Arthritis
